Vimarsana
Biggest News Aggregation in the World

Clinical Actionability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Actionability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Actionability Today - Breaking & Trending Today

Forget lung, breast or prostate cancer: why tumour naming needs to change - Vimarsana News

Forget lung, breast or prostate cancer: why tumour naming needs to change

The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.

Source: nature.com
DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab - Vimarsana News

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.

Should Every Cancer Patient Have Next-Generation Sequencing? - Vimarsana News

Should Every Cancer Patient Have Next-Generation Sequencing?

Patients with cancer are increasingly having tumor DNA sequenced to identify disease markers and potential targets, but some investigators question whether every cancer patient can benefit.

New tool launched to make ESMO Clinical Practice Guidelines easier to use in routine clinical practice - Vimarsana News

New tool launched to make ESMO Clinical Practice Guidelines easier to use in routine clinical practice

ESMO, the leading professional organization for medical oncology, today announced the launch of a new tool designed to make the renowned ESMO Clinical Practice Guidelines (CPGs) easier to use in oncologists' routine clinical practice and support optimal decision-making in a rapidly evolving medical field.

Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds - Vimarsana News

Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds

The availability of multi-gene tests was most inconsistent across 53 European countries, and reimbursement was seen as the greatest barrier.